ERBB2 and breast carcinoma: A recent study showed that ibrutinib is an effective inhibitor of HER2 and that treatment with ibrutinib completely abrogated the phosphorylation of HER2 and potently inhibited the cell viability of HER2‐positive breast cancer cells 21.